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Abstract 
We report a patient with unknown primary undifferentiated carcinoma who developed 
acute renal failure associated with interstitial fibrosis following pemetrexed therapy. 
Despite drug withdrawal, renal function remained altered and the patient experienced 
chronic renal insufficiency. Pemetrexed disodium (AlimtaTM) is a multitargeted antifolate 
agent approved by the Food and Drug Administration (FDA) for patients diagnosed with 
mesothelioma and non-small cell lung cancer. This drug is almost exclusively cleared by 
renal excretion [1]. The most common side effects are hematologic dose-limiting 
toxicities and nonhematologic toxicities including fatigue, diarrhea, nausea, mucositis 
and rash. Although few cases of renal failure have been published, no study has reported 
on the renal pathological findings in this setting. We present a case of acute tubular 
necrosis associated with interstitial fibrosis after pemetrexed therapy. 
 
Case Report 
A 53-year-old African man was diagnosed with unknown primary undifferentiated carcinoma with 
mediastinal lymph nodes and thrombosis of superior vena cava in 1993. Comorbidities included 
hepatitis B and C virus infections. The patient was initially treated by 8 cycles of CHOP 
(cyclophosphamide, Adriamycin, vincristine, and prednisone). He relapsed in 1996 with spinal bone 
metastases treated by laminectomy, radiotherapy and PFL-VP16 (CDDP, 5FU, leucovorin, etoposide). 
In 1999 he relapsed again with mediastinal lymph nodes treated by 3 cycles of Navelbine and cisplatin 
followed by 3 cycles of carboplatin and Navelbine with >70% treatment response. Biopsy at that time 
revealed large-cell carcinoma of bronchial or thymic origin. In 2002 newly discovered bone, pulmonary 
and mediastinal metastases were treated successively with Taxotere/gemcitabine (6 cycles), 
Navelbine/Xeloda (6 cycles), Iressa (6 months) and Tarceva (8 months). In 2005, pemetrexed was  
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maintained for only 4 cycles, then was suspended due to hematoxicity despite clinical efficiency. His 
performance status remained acceptable estimated at 1. No maintenance treatment was used until April 
2007, when new bone metastases were discovered. The patient was hence treated with pemetrexed, as it 
once showed its efficacy in 2005. Baseline serum creatinine was 100 μmol/l. After the sixth cycle, 
laboratory examination revealed serum creatinine 400 μmol/l, metabolic acidosis (plasma bicarbonate 
21 mmol/l), sodium 145 mmol/l, potassium 4,5 mmol/l, urea 21 mmol/l. The rate of creatinine clearance 
was 10 ml/min. A 24-h urine collection on the 2nd hospital day revealed a 0.55 g proteinuria without 
hematuria or leukocyturia. 
A kidney biopsy was performed showing acute tubular necrosis (ATN) associated with chronic 
interstitial fibrosis (fig. 1). The patient underwent intravenous hydration, urine alkalinisation and 
folinic acid supplementation. The renal function partially recovered within 1 month (serum creatinine 
400 μmol/l). 
His current renal function remained stable after 6 months follow-up of the acute renal failure (ARF) 
episode with a stable serum creatinine level of 380 μmol/l. He is treated with oral VP 16. 
Discussion 
Our patient experienced severe acute kidney injury related to ATN and interstitial 
fibrosis following sequential treatment with pemetrexed for a metastatic undifferentiated 
carcinoma. Although our patient had previously received cisplatin, ARF appeared only 
after pemetrexed treatment. 
Only few cases of ARF due to pemetrexed have been reported. In a patient treated for 
metastatic non-small cell lung cancer, ARF was associated with nephrogenic diabetes 
insipidus and distal renal tubular acidosis following 3 doses of pemetrexed (500 mg/m
2). 
At discharge 1 month after admission, the patient still demonstrated polyuria, 
hypokalemia, and metabolic acidosis despite recovery to a creatinine level of 1.7 mg/dl 
[2]. 
In a second patient with unresectable pleural mesothelioma, pemetrexed (500 mg/m
2) 
and cisplatin (75 mg/m
2) for 3 cycles, then pemetrexed as a single agent induced ARF 
appearing at the sixth cycle of pemetrexed [3]. Unfortunately, kidney biopsy was not 
performed. In both cases, ARF was associated with myelosuppression. 
Eighteen cases of renal failure during clinical trials of pemetrexed [2] have also been 
reported. In the phase I pemetrexed maintenance therapy (PMT) study evaluating toxicity 
as primary end point, 8% of patients with malignant pleural mesothelioma treated with 
high doses (700 mg/m
2) of pemetrexed experienced reversible grade 1 or 2 renal failure: 
creatinine clearance decreased from 88 ± 21 ml/min at the end of the induction therapy to 
77 ± 26 ml/min at the end of maintenance therapy (p < 0.05). No grade 4 toxicity was 
observed [4]. 
In phase III trials, all grades of renal failure and grade 4 requiring dialysis were 
reported in 2.4 and 0.6% of patients, respectively [5]. In all studies, baseline creatinine 
clearance (estimated using the Cockcroft-Gault formula) less than 60 ml/min was an 
exclusion criterion. Indeed, pemetrexed-induced renal toxicity may potentiate an 
enhanced myelosuppressive response to pemetrexed. In an initial phase I study [6] the 
development of severe toxicity appeared to correlate most strongly with baseline renal 
function. Patients with an estimated creatinine clearance value less than 80 ml/min were 
more likely to develop severe myelosuppression (grade IV neutropenia) than those with a 
creatinine clearance more than 80 ml/min. This suggests that initial dosing should be 
based on the area under the curve as currently utilized for carboplatin rather than on 
body surface area and renal function. This idea was confirmed by an analysis of 10 phase  
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II clinical trials [7]. In a phase I dose escalation trial including patients with various 
degrees of renal dysfunction [8], pemetrexed seems to be well tolerated at doses of 500 
mg/m
2 with vitamin supplementation in the case of creatinine clearance ≥40 ml/min. The 
FDA even recommends a creatinine clearance of greater than 45 ml/min as the threshold 
for administering the drug [9]. 
Antifolate nephrotoxicity is correlated with renal reabsorption. An experimental study 
demonstrated that in kidney proximal tubule, the folic acid is reabsorbed via renal folate 
receptors and brush-border membrane vesicles. The reabsorption of folic acid is increased 
in acid pH. The observed binding is 3-fold higher at pH 6.0 than at 7.0 [10]. The 
hypothesis is that the antifolate, like the folic acid, would be less reabsorbed by urine 
alkalinisation and increasing urine flow rate by hydration. On the other hand, thymidine 
is described as an antidote for pemetrexed-related toxicity in a clinical report, though in 
that report the concomitant use of hemodialysis complicates the interpretation of this 
favorable outcome [3]. In summary, pemetrexed therapy may induce ATN associated 
with interstitial fibrosis leading to chronic renal failure. 
 
 
 
 
 
Fig. 1. Acute tubular injury is characterized by swelling and vacuolization of proximal tubular cells. 
Cells appear large and contain discrete vacuoles of varying size. Masson’s trichrome. Original 
magnification ×200. 
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